Hyperlipoproteinemia causes

Lipoprotein Disorders Main Page
	Hyperlipoproteinemia Microchapters
Hypercholesterolemia Patient Information
Hypertriglyceridemia Patient Information
Overview
Classification Familial hyperchylomicronemia Familial hypercholesterolemia Familial combined hyperlipidemia Dysbetalipoproteinemia Primary hypertriglyceridemia Mixed hyperlipoproteinemia
Differential Diagnosis
Screening
ACC/AHA Guideline Recommendations
Summary
Treatment
Major recommendations for statin therapy
Therapeutic response to statin therapy
Blood cholesterol LDL and non-HDL treatment goals
Treatment in heart failure and hemodialysis
Primary prevention
Secondary prevention
Intensity of statin therapy in primary and secondary prevention
Safety Recommendations
Guideline on Lifestyle Management

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ogheneochuko Ajari, MB.BS, MS [2]

Overview

The causes of hyperlipoproteinemia are either familial, acquired or idiopathic. Familial (primary) causes are mainly due to genetic abnormalities and a few examples include familial hypercholesterolemia, familial combined hyperlipidemia and familial hypertriglyceridemia. Acquired (secondary) hyperlipoproteinemia often mimic primary forms of hyperlipoproteinemia and common causes include the use of drugs (diuretics, beta blockers and estrogens); endocrine disorders (diabetes mellitus, hypothyroidism); metabolic disorders and renal causes such as renal failure.

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.

Acute renal failure

Common Causes

Causes Based on Major Lipoprotein Detected in Blood Laboratory Test

High Chylomicron Causes

High Chylomicron Remnant Causes

High HDL Causes

High IDL Causes

High LDL Causes

High VLDL Causes

High Total Cholesterol Causes

High Triglyceride Causes

Combined List of Causes in Alphabetical Order

References

↑ Kasiske BL, Ma JZ, Kalil RS, Louis TA (1995). "Effects of antihypertensive therapy on serum lipids". Ann Intern Med. 122 (2): 133–41. PMID 7992988.
↑ Boers M, Nurmohamed MT, Doelman CJ, Lard LR, Verhoeven AC, Voskuyl AE; et al. (2003). "Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis". Ann Rheum Dis. 62 (9): 842–5. PMC 1754645. PMID 12922956.
↑ ^3.0 ^3.1 ^3.2 ^3.3 Durrington, P. (2003). "Dyslipidaemia". Lancet. 362 (9385): 717–31. doi:10.1016/S0140-6736(03)14234-1. PMID 12957096. Unknown parameter |month= ignored (help)
↑ Genest JJ, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH; et al. (1992). "Familial lipoprotein disorders in patients with premature coronary artery disease". Circulation. 85 (6): 2025–33. PMID 1534286.
↑ ^5.0 ^5.1 ^5.2 ^5.3 Covington, MB. (2004). "Omega-3 fatty acids". Am Fam Physician. 70 (1): 133–40. PMID 15259529. Unknown parameter |month= ignored (help)
↑ ^6.0 ^6.1 ^6.2 Yoshimura, T.; Ito, M.; Sakoda, Y.; Kobori, S.; Okamura, H. (1998). "Rare case of autoimmune hyperchylomicronemia during pregnancy". Eur J Obstet Gynecol Reprod Biol. 76 (1): 49–51. PMID 9481547. Unknown parameter |month= ignored (help)
↑ ^7.0 ^7.1 Weintraub M, Burstein A, Rassin T, Liron M, Ringel Y, Cabili S; et al. (1992). "Severe defect in clearing postprandial chylomicron remnants in dialysis patients". Kidney Int. 42 (5): 1247–52. PMID 1453610.
↑ ^8.0 ^8.1 Ito M, Takamatsu J, Matsuo T, Kameoka K, Kubota S, Fukata S; et al. (2003). "Serum concentrations of remnant-like particles in hypothyroid patients before and after thyroxine replacement". Clin Endocrinol (Oxf). 58 (5): 621–6. PMID 12699445.
↑ ^9.0 ^9.1 Benjó AM, Maranhão RC, Coimbra SR, Andrade AC, Favarato D, Molina MS; et al. (2006). "Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: effects of niacin treatment". Atherosclerosis. 187 (1): 116–22. doi:10.1016/j.atherosclerosis.2005.08.025. PMID 16458316.
↑ ^10.0 ^10.1 Brasaemle DL, Cornely-Moss K, Bensadoun A (1993). "Hepatic lipase treatment of chylomicron remnants increases exposure of apolipoprotein E." J Lipid Res. 34 (3): 455–65. PMID 8468529.
↑ ^11.0 ^11.1 Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H (1999). "Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients". Kidney Int Suppl. 71: S134–6. PMID 10412757.
↑ ^12.0 ^12.1 ^12.2 ^12.3 ^12.4 ^12.5 Nishizawa Y, Shoji T, Kawagishi T, Morii H (1997). "Atherosclerosis in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation". Kidney Int Suppl. 62: S90–2. PMID 9350691.
↑ ^13.0 ^13.1 Oi K, Hirano T, Sakai S, Kawaguchi Y, Hosoya T (1999). "Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients". Kidney Int Suppl. 71: S227–8. PMID 10412783.
↑ ^14.0 ^14.1 Durrington PN (1993). "Diabetes, hypertension and hyperlipidaemia". Postgrad Med J. 69 Suppl 1: S18–25, discussion S25-9. PMID 8497453.
↑ ^15.0 ^15.1 Shoji T, Emoto M, Kawagishi T, Kimoto E, Yamada A, Tabata T; et al. (2001). "Atherogenic lipoprotein changes in diabetic nephropathy". Atherosclerosis. 156 (2): 425–33. PMID 11395040.
↑ ^16.0 ^16.1 Geberhiwot T, Alger S, McKiernan P, Packard C, Caslake M, Elias E; et al. (2007). "Serum lipid and lipoprotein profile of patients with glycogen storage disease types I, III and IX". J Inherit Metab Dis. 30 (3): 406. doi:10.1007/s10545-007-0485-2. PMID 17407002.
↑ ^17.0 ^17.1 Levy E, Thibault LA, Roy CC, Bendayan M, Lepage G, Letarte J (1988). "Circulating lipids and lipoproteins in glycogen storage disease type I with nocturnal intragastric feeding". J Lipid Res. 29 (2): 215–26. PMID 3130454.
↑ ^18.0 ^18.1 Pejic, RN.; Lee, DT. "Hypertriglyceridemia". J Am Board Fam Med. 19 (3): 310–6. PMID 16672684.
↑ ^19.0 ^19.1 ^19.2 Kronenberg, F. (2005). "Dyslipidemia and nephrotic syndrome: recent advances". J Ren Nutr. 15 (2): 195–203. PMID 15827892. Unknown parameter |month= ignored (help)
↑ ^20.00 ^20.01 ^20.02 ^20.03 ^20.04 ^20.05 ^20.06 ^20.07 ^20.08 ^20.09 ^20.10 ^20.11 ^20.12 ^20.13 ^20.14 ^20.15 ^20.16 ^20.17 ^20.18 ^20.19 ^20.20 ^20.21 ^20.22 ^20.23 ^20.24 ^20.25 ^20.26 ^20.27 Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP (2009). "Primary and secondary hypertriglyceridaemia". Curr Drug Targets. 10 (4): 336–43. PMID 19355858.
↑ ^21.0 ^21.1 Fallat RW, Glueck CJ (1976). "Familial and acquired type V hyperlipoproteinemia". Atherosclerosis. 23 (1): 41–62. PMID 1078394.

[pmid7992988-1] Kasiske BL, Ma JZ, Kalil RS, Louis TA (1995). "Effects of antihypertensive therapy on serum lipids". Ann Intern Med. 122 (2): 133–41. PMID 7992988.

[pmid12922956-2] Boers M, Nurmohamed MT, Doelman CJ, Lard LR, Verhoeven AC, Voskuyl AE; et al. (2003). "Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis". Ann Rheum Dis. 62 (9): 842–5. PMC 1754645. PMID 12922956.

[Durrington-2003-3] 3.0 ^3.1 ^3.2 ^3.3 Durrington, P. (2003). "Dyslipidaemia". Lancet. 362 (9385): 717–31. doi:10.1016/S0140-6736(03)14234-1. PMID 12957096. Unknown parameter |month= ignored (help)

[pmid1534286-4] Genest JJ, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH; et al. (1992). "Familial lipoprotein disorders in patients with premature coronary artery disease". Circulation. 85 (6): 2025–33. PMID 1534286.

[Covington-2004-5] 5.0 ^5.1 ^5.2 ^5.3 Covington, MB. (2004). "Omega-3 fatty acids". Am Fam Physician. 70 (1): 133–40. PMID 15259529. Unknown parameter |month= ignored (help)

[Yoshimura-1998-6] 6.0 ^6.1 ^6.2 Yoshimura, T.; Ito, M.; Sakoda, Y.; Kobori, S.; Okamura, H. (1998). "Rare case of autoimmune hyperchylomicronemia during pregnancy". Eur J Obstet Gynecol Reprod Biol. 76 (1): 49–51. PMID 9481547. Unknown parameter |month= ignored (help)

[pmid1453610-7] 7.0 ^7.1 Weintraub M, Burstein A, Rassin T, Liron M, Ringel Y, Cabili S; et al. (1992). "Severe defect in clearing postprandial chylomicron remnants in dialysis patients". Kidney Int. 42 (5): 1247–52. PMID 1453610.

[pmid12699445-8] 8.0 ^8.1 Ito M, Takamatsu J, Matsuo T, Kameoka K, Kubota S, Fukata S; et al. (2003). "Serum concentrations of remnant-like particles in hypothyroid patients before and after thyroxine replacement". Clin Endocrinol (Oxf). 58 (5): 621–6. PMID 12699445.

[pmid16458316-9] 9.0 ^9.1 Benjó AM, Maranhão RC, Coimbra SR, Andrade AC, Favarato D, Molina MS; et al. (2006). "Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: effects of niacin treatment". Atherosclerosis. 187 (1): 116–22. doi:10.1016/j.atherosclerosis.2005.08.025. PMID 16458316.

[pmid8468529-10] 10.0 ^10.1 Brasaemle DL, Cornely-Moss K, Bensadoun A (1993). "Hepatic lipase treatment of chylomicron remnants increases exposure of apolipoprotein E." J Lipid Res. 34 (3): 455–65. PMID 8468529.

[pmid10412757-11] 11.0 ^11.1 Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H (1999). "Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients". Kidney Int Suppl. 71: S134–6. PMID 10412757.

[pmid9350691-12] 12.0 ^12.1 ^12.2 ^12.3 ^12.4 ^12.5 Nishizawa Y, Shoji T, Kawagishi T, Morii H (1997). "Atherosclerosis in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation". Kidney Int Suppl. 62: S90–2. PMID 9350691.

[pmid10412783-13] 13.0 ^13.1 Oi K, Hirano T, Sakai S, Kawaguchi Y, Hosoya T (1999). "Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients". Kidney Int Suppl. 71: S227–8. PMID 10412783.

[pmid8497453-14] 14.0 ^14.1 Durrington PN (1993). "Diabetes, hypertension and hyperlipidaemia". Postgrad Med J. 69 Suppl 1: S18–25, discussion S25-9. PMID 8497453.

[pmid11395040-15] 15.0 ^15.1 Shoji T, Emoto M, Kawagishi T, Kimoto E, Yamada A, Tabata T; et al. (2001). "Atherogenic lipoprotein changes in diabetic nephropathy". Atherosclerosis. 156 (2): 425–33. PMID 11395040.

[pmid17407002-16] 16.0 ^16.1 Geberhiwot T, Alger S, McKiernan P, Packard C, Caslake M, Elias E; et al. (2007). "Serum lipid and lipoprotein profile of patients with glycogen storage disease types I, III and IX". J Inherit Metab Dis. 30 (3): 406. doi:10.1007/s10545-007-0485-2. PMID 17407002.

[pmid3130454-17] 17.0 ^17.1 Levy E, Thibault LA, Roy CC, Bendayan M, Lepage G, Letarte J (1988). "Circulating lipids and lipoproteins in glycogen storage disease type I with nocturnal intragastric feeding". J Lipid Res. 29 (2): 215–26. PMID 3130454.

[Pejic--18] 18.0 ^18.1 Pejic, RN.; Lee, DT. "Hypertriglyceridemia". J Am Board Fam Med. 19 (3): 310–6. PMID 16672684.

[Kronenberg-2005-19] 19.0 ^19.1 ^19.2 Kronenberg, F. (2005). "Dyslipidemia and nephrotic syndrome: recent advances". J Ren Nutr. 15 (2): 195–203. PMID 15827892. Unknown parameter |month= ignored (help)

[pmid19355858-20] 20.00 ^20.01 ^20.02 ^20.03 ^20.04 ^20.05 ^20.06 ^20.07 ^20.08 ^20.09 ^20.10 ^20.11 ^20.12 ^20.13 ^20.14 ^20.15 ^20.16 ^20.17 ^20.18 ^20.19 ^20.20 ^20.21 ^20.22 ^20.23 ^20.24 ^20.25 ^20.26 ^20.27 Kolovou GD, Anagnostopoulou KK, Kostakou PM, Bilianou H, Mikhailidis DP (2009). "Primary and secondary hypertriglyceridaemia". Curr Drug Targets. 10 (4): 336–43. PMID 19355858.

[pmid1078394-21] 21.0 ^21.1 Fallat RW, Glueck CJ (1976). "Familial and acquired type V hyperlipoproteinemia". Atherosclerosis. 23 (1): 41–62. PMID 1078394.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

[20]

[21]

v t e Lipopedia
Basic Science	Cholesterol • Triglyceride Lipoprotein metabolism and transport Lipoprotein: Chylomicron • Chylomicron remnant • HDL • IDL • LDL • Lipoprotein(a) • VLDL • Lipoprotein-X Apolipoprotein: APOA (1, 2, 4, 5) • APOB ( Apolipoprotein B-48, Apolipoprotein B-100) • APOC (1, 2, 3, 4) • APOD • APOE • APOH • APOJ • APOL • APOM • Apo(a) Lipoprotein receptor: LDL receptor • Soluble low density lipoprotein receptor-related protein (sLRP) • Apolipoprotein E Receptor 2 • Scavenger receptor • Scavenger receptor A • Scavenger receptor B • VLDL receptor Lipoprotein enzymes: Lipoprotein lipase • Lipoprotein-associated phospholipase A2 (Lp-PLA2) • Cholesterylester transfer protein ( Acetyl-CoA C-acyltransferase, Lecithin-cholesterol acyltransferase) • Microsomal triglyceride transfer protein • ABCA1 Genes: Low density lipoprotein receptor gene family • Microsomal triglyceride transfer protein • ABCA1
Lipoprotein Disorders	Lipoprotein disorders Primary lipoprotein disorders: Familial hyperchylomicronemia (Type I) • Familial hypercholesterolemia (Type IIA) • Familial combined hyperlipidemia (Type IIB) • Dysbetalipoproteinemia (Type III) • Primary hypertriglyceridemia (Type IV) • Mixed hyperlipoproteinemia (Type V) Secondary lipoprotein disorders
Abnormal Laboratory Lipid Profile	Low chylomicron • Low chylomicron remnant • Low HDL • Low IDL • Low LDL • Low lipoprotein(a) • Low VLDL High chylomicron • High chylomicron remnant • High HDL • High IDL • High LDL • High Lipoprotein(a) • High VLDL